PRISM Mid-Day Movers: Global Health and Biotech are Today’s Leaders.
Shares of Longeveron Inc. (ticker: LGVN) are ripping higher today, with the stock recently up about 71% as traders react to a string of positive stem‑cell trial updates and fresh financing that extends the company’s cash runway into late 2026. The bounce comes after Longeveron reported statistically significant Phase 2b results showing its lead cell therapy, laromestrocel, improved functional capacity in elderly frailty patients and delivered encouraging neuroinflammation and brain‑volume signals in Alzheimer’s disease, while an up‑to‑$30 million private placement/ATM structure gives the micro‑cap more breathing room to advance pivotal studies and align on endpoints with the FDA in upcoming Type C meetings.
Shares of Polaryx Therapeutics, Inc. (ticker: PLYX) are moving higher again today, recently trading around $3.52 and up roughly 22–23% as momentum money continues to flow into this tightly held rare‑disease biotech. With the stock now more than 90% higher year‑to‑date and volume running well above its average, today’s 20‑plus percent pop looks like a continuation of the speculative bid that followed its recent Nasdaq direct listing, Maxim Group’s Buy initiation with a $10 target, and progress toward launching the SOTERIA Phase 2 basket trial of lead candidate PLX‑200 across multiple lysosomal storage disorders.
Other Notable Movers:
LifeMD (LFMD) up 20%
Hepion Pharmaceuticals (HEPA) up 19%
Allurion (ALUR) down -45%
